Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
3.490
-0.210 (-5.68%)
May 15, 2026, 4:00 PM EDT - Market closed
Akari Therapeutics, Stock Forecast
AKTX's stock price has decreased by -93.54% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 3 analysts polled by S&P Global, Akari Therapeutics, stock has a consensus rating of "Buy" and an average price target of $153.39. The average 1-year stock price forecast is 4,295.13% higher than the current stock price, while the lowest is $26.78 (+667.34%) and the highest is $280 (+7,922.92%).
Price Target: $153.39 (+4,295.13%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 1, 2026.
Analyst Ratings
The average analyst rating for Akari Therapeutics, stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 8, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $1.6 → $27 | Strong Buy | Maintains | $1.6 → $27 | +673.64% | Apr 1, 2026 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +1,046.13% | Jan 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $64 | Strong Buy | Reiterates | $64 | +1,733.81% | Sep 9, 2025 |
| Maxim Group | Maxim Group | Strong Buy Initiates $200 | Strong Buy | Initiates | $200 | +5,630.66% | Jul 18, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-4.53
from -20.55
EPS Next Year
-4.76
from -4.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -4.53 | -4.76 | |
| Low | -11.76 | -13.72 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.